Document is current
Any future updates will be listed below
-
Authors
Winkelmann, Michael
Achhammer, Philipp
Blumenberg, Viktoria
Rejeski, Kai
Bücklein, Veit L.
Schmidt, Christian
Sheikh, Gabriel T.
Brendel, Matthias
Ricke, Jens
von Bergwelt-Baildon, Michael
Subklewe, Marion
Kunz, Wolfgang G.
-
Funding
Funding for this research was provided by:
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 1 December 2024
Accepted: 10 November 2025
First Online: 22 November 2025
Declarations
:
: All medical records and imaging studies were reviewed with the approval of the LMU Munich Institutional Review Board (LMU Ethics Committee, project number 19–817).
: Informed consent was obtained from all individual participants included in the study.
: V.B.: BMS/Celgene: Research Funding; Kite/Gilead: Consultancy, Honoraria, Research Funding; Janssen: Research Funding, Honoraria; Novartis: Research Funding, Honoraria,; Roche: Research Funding; Takeda: Research Funding. K.R.: Kite/Gilead: Research Funding, Consultancy, Honoraria and travel support; Novartis: Honoraria; BMS/Celgene: Consultancy, Honoraria; Pierre-Fabre: travel support. V.L.B.: Amgen: Honoraria; Celgene/BMS: Research Funding; Kite/Gilead: Research Funding, Honoraria; Novartis: Honoraria; Pfizer: Honoraria. C.S.: Kite/Gilead: Travel Support. M.B.: Life Molecular Imaging: Consultancy, Honoraria; MIAC: Consultancy, Honoraria; GE healthcare: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Life Molecular Imaging: Honoraria. M.v.B.: Astellas: Consultancy, Research Funding and Honoraria; BMS: Consultancy, Research Funding and Honoraria; Kite/Gilead: Consultancy, Research Funding and Honoraria; Miltenyi: Consultancy, Research Funding and Honoraria; Mologen: Consultancy, Research Funding and Honoraria; MSD Sharp & Dohme: Consultancy, Research Funding and Honoraria; Novartis: Consultancy, Research Funding and Honoraria; Roche: Consultancy, Research Funding and Honoraria. M.S.: Amgen: Research Funding, Speakers Bureau; Astra Zeneca: Speakers Bureau; Aven Cell: Consultancy, BMS/Celgene: Research Funding, Speakers Bureau; CDR-Life: Consultancy, Gilead: Research Funding, Speakers Bureau; GSK: Speakers Bureau; Ichnos Sciences: Consultancy; Incyte Biosciences: Consultancy; Janssen: Research Funding, Consultancy, Speakers Bureau; Miltenyi Biotec: Research Funding, Consultancy; Morphosys: Research Funding; Molecular Partners: Consultancy; Novartis: Research Funding, Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Roche: Research Funding, Speakers Bureau; Seattle Genetics: Research Funding; Takeda: Research Funding, Consultancy, Speakers Bureau. W.G.K.: Bristol Myers Squibb: Advisor; Boehringer Ingelheim: Advisor; mintMedical: Advisor, Need, Inc.: Advisor. The remaining authors declare no competing financial interests. None of the mentioned conflicts of interest were related to financing of the content of this manuscript.
